Introduction
Genetic Generalized Epilepsy (GGE) accounts for 15-20% of cases of epilepsy 1 . Most patients are rendered seizure free with first-line antiseizure drugs (ASD), which are effective in generalized tonic-clonic seizures (GTCS), absence or myoclonic seizures. Approximately 15% of patients are refractory to these ASD 2 . In this subgroup, GTCS are the most incapacitating seizures, and other ASD are required.
Classic ASD that exert their action through fast blocking of the sodium channel can be effective on GTCS, but they have the potential to aggravate absences and myoclonia 3 .
Status of absences and myoclonia have been described with carbamacepine, oxcarbacepine and phenytoin 4 . Lamotrigine, which is one of the drugs of choice in GGE, has also a potential of aggravating myoclonia that is lower than the other classic sodium channel blockers [5] [6] .
Unlike classic sodium channel blockers, that facilitate the fast inactivation of sodium channel, lacosamide (LCM) facilitates the slow inactivation of this channel 7 .
First developed for focal epilepsies, LCM was successful in controlling GTCS in GGE in some case series [8] [9] [10] [11] and in a recently published safety open label study 12 . However, in this study, 10% of patients suffered an aggravation of absences. Thus, further investigation on its efficacy/aggravation profile over different type of seizures in GGE is highly valuable.
The aim of our observational study was to asses if LCM was effective on GTCS in a series of patients with GGE and to control the aggravation or appearance of absences/myoclonia. For this purpose, and in contrast to first case series, video-EEG (VEEG) was performed during the follow-up. The primary efficacy endpoint was responder rate: percentage of patients achieving ≥ 50% reduction in GTCS frequency during the 6 months after LCM initiation compared to the 6 months before. Besides, we reviewed the total period of follow-up of patients to exclude posterior aggravations, measure the duration of seizure freedom, register other side effects and changes on ASD regimen.
Material and methods
To reinforce the identification of any aggravation of absences/myoclonia, a 24
hours VEEG was programmed in all patients during the 6-12 weeks after LCM initiation. Additionally, we explored the subjective impression of patients by asking if absences or myoclonia had aggravated.
Results
We identified 9 patients with GGE and persistent GTCS. Demographic and clinical data are illustrated in tables 1&2. In addition to GTCS, two of the 9 patients had refractory absences, and one had absences, myoclonia and GTCS in the 6 months before LCM treatment onset.
Eight patients were currently or had been on valproate (VPA). Only one female (1, table 2) was not treated with VPA to avoid adverse effects. 
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LCM was prescribed on a median daily dose of 300 mg (200-400). Patients received an initial dose of 50 mg twice a day in the first week, which was increased in 50 or 100 mg increments per week depending on response and tolerance. In one patient (3, table 2) titration of LCM was made at the same time than progressive tapering of topiramate. In the remaining 8, no change of other ASDs was made during the titration or maintenance on LCM.
Results on GTCS:
Seven out of 9 patients were responders (1-7, table 2). Seizure freedom periods achieved on LCM were longer than one year in all of them. In two cases they were longer than 5 years.
One of the two non-responders (8, 
Effect on absences and myoclonia:
Among the three patients with absences in the 6-months before the initiation of LCM, two denied an aggravation in these seizures. The remaining patient (case 7, Apart from those three cases, two patients had experienced absences in the past (not in the 6 months before LCM onset). One is case 9, a 58 year old male with Juvenile Absences Epilepsy. His absences were controlled and he was started on LCM 150 mg/24h added to lamotrigine 400 mg/24h for persistent GTCS. He remained seizure free until month 4, when he suffered a status. Semiology was described by witness as ongoing absences with arms myoclonia that evolved after half an hour to a GTCS with postictal agitation. LCM was withdrawn. He denied previous history of myoclonia. The other one is patient 4, who had a past history of absences status on carbamazepine. He was started on LCM for very persistent GTCS. He did not suffer any aggravation and remains seizure free after 5 years.
The only patient who suffered myoclonia in the 6 months previous to LCM (6, table 2) reported a significant reduction. There was a second patient with JME who had suffered myoclonia in the past (1, table 2). He did not report reappearance.
Follow-up:
A patients remain on LCM. There were no aggravations after the 6 first months. Patients did not report other side effects.
VEEG findings:
A 24 hours VEEG on LCM was performed in 8 patients. It was normal in 2 patients (1&4, table 2), whose previous EEG had shown generalized spike-and-wave discharges. Two more patients had moderately persistent generalized epileptiform discharges only during sleep (3&5, table 2). They had not prolonged VEEG before LCM to compare with. In two other cases (2&6, table 2) VEEG showed low persistent generalized spike-and-wave discharges. Comparisons to prolonged VEEG before LCM demonstrated reduction of persistence and duration of discharges on LCM in both cases, and disappearance of hyperventilation-induced absences in one of them. In all these 6 cases VEEG findings were in line with their clinical responder status.
The remaining clinical responder (7, 
Discussion
In this case series of 9 patients with GGE in a regular clinical-setting, LCM has been an effective option for the treatment of refractory GTCS. The high responder rate 
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Regarding myoclonia, the status suffered by a patient without previous history of myoclonia suggests that it could be possible to trigger de novo seizures of this type.
As far as we know, this is the first myoclonia and absences status reported with LCM.
Recently, another case of unmasking of myoclonia in a patient with GGE on LCM was reported 15 (not a status). In our study, the combination of LCM and lamotrigine could have also facilitated the aggravation. Our study adds to previous literature the report of a case of status of myoclonia and absences, new data regarding efficacy of 24 hours VEEG to detect aggravations, as well as further evidence supporting efficacy of LCM on GTCS in GGE. On the other hand, it has the limitations of a small sample size, the retrospective character of data collection for baseline seizure frequency, and the inclusion of a small number of cases with absences and myoclonia that could be prone to aggravate.
Conclusions
In agreement with previous clinical evidence, our results suggest that LCM can be a reasonable option for patients with GGE and persistent GTCS. During the followup, it should be considered to perform prolonged VEEG in addition to the clinical surveillance, specially in patients with a history of absences who could have a higher risk of worsening. Unmasking of myoclonia, even in the form of status, is also a potential risk, whose quantification needs further clinical research.
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